Browse Drug Recalls
10 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 10 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 10 FDA drug recalls.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| Nov 22, 2019 | Ranitidine Syrup Oral Solution 15 mg/mL 6. fl. oz. (473 mL), NDC 65162-664-90. | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | Amneal Pharmaceuticals, Inc. |
| Nov 22, 2019 | Ranitidine Tablets, USP 150 mg, 1000-count bottles, NDC 53746-253-10. | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | Amneal Pharmaceuticals, Inc. |
| Nov 22, 2019 | Ranitidine Tablets, USP 150 mg a).60-count bottles (NDC 65162-253-06) , b).1... | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | Amneal Pharmaceuticals, Inc. |
| Nov 22, 2019 | Ranitidine Tablets, USP 300 mg, 250-count bottles, NDC 53746-254-02. | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | Amneal Pharmaceuticals, Inc. |
| Nov 22, 2019 | Ranitidine Tablets, USP 300 mg - a).30-count bottles (NDC 65162-254-30), b).1... | CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API | Class II | Amneal Pharmaceuticals, Inc. |
| Oct 16, 2019 | Isotretinoin Capsules, USP 10 mg. Rx Only, 3 Prescription Blister Packs of 10... | Failed Impurities/Degradation Specifications: Tretinoin levels slightly above specification limits. | Class III | Amneal Pharmaceuticals, Inc. |
| Sep 24, 2019 | Benazepril HCl Tablets, USP 40 mg, 100 count bottles, Rx only, Distributed by... | Presence of Foreign Tablet/Capsule; Promethazine HCl tablet found in the Benazepril HCl bottle | Class III | Amneal Pharmaceuticals, Inc. |
| Jul 18, 2019 | Methylergonovine Maleate USP 0.2 mg Tablets a) 12 count (NDC 69238-1605-02) ... | Presence of Foreign Tablet/Capsule; one Promethazine tablet was found in a bottle of Methylergono... | Class III | Amneal Pharmaceuticals, Inc. |
| Sep 25, 2017 | Esterified Estrogens & Methyltestosterone Tablets, USP 0.625 mg/1.25 mg, 100... | Subpotent Drug: Out of specification assay result in Esterified Estrogen and Methyltestosterone t... | Class III | Amneal Pharmaceuticals, Inc. |
| Sep 25, 2017 | Esterified Estrogens & Methyltestosterone Tablets, USP 1.25 mg/2.5 mg, 100-c... | Subpotent Drug: Out of specification assay result in Esterified Estrogen and Methyltestosterone t... | Class III | Amneal Pharmaceuticals, Inc. |
Frequently Asked Questions
When a drug safety issue is identified — through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks — the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.